A cure for Enron flu

pills-jpg

The energy trading industry is at a crossroads. The failure of Enron has removed the dominant industry participant, and repercussions are still being felt. Stock prices for the entire sector have fallen and investors and analysts remain extremely skittish. Rating agencies are pushing trading companies for much greater business detail and downgrades have become common rumours.

Even to a casual observer, it is obvious the energy industry is sick. But the cause of the illness is unclear

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

If you already have an account, please sign in here.

Counting down to dollar Libor transition

In a Risk.net webinar, experts discussed the impact of market volatility on Libor transition, the availability of term SOFR, developments in non-linear markets and management of forthcoming CCP conversions

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here